JMP Securities Reiterates Market Outperform Rating for Benitec Biopharma (NASDAQ:BNTC)

JMP Securities reaffirmed their market outperform rating on shares of Benitec Biopharma (NASDAQ:BNTC) in a report published on Wednesday,Benzinga reports. JMP Securities currently has a $20.00 price target on the biotechnology company’s stock.

Other research analysts have also recently issued research reports about the stock. TD Cowen began coverage on shares of Benitec Biopharma in a report on Monday, July 7th. They issued a “buy” rating for the company. Oppenheimer reaffirmed an “outperform” rating and issued a $29.00 price target (down previously from $35.00) on shares of Benitec Biopharma in a report on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $24.80.

Benitec Biopharma Stock Performance

Shares of BNTC stock opened at $14.09 on Wednesday. Benitec Biopharma has a 52-week low of $8.49 and a 52-week high of $17.15. The company has a quick ratio of 14.80, a current ratio of 14.80 and a debt-to-equity ratio of 0.01. The stock has a market cap of $369.86 million, a PE ratio of -9.58 and a beta of 0.43. The business has a 50-day simple moving average of $12.65 and a 200-day simple moving average of $13.47.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings results on Thursday, September 25th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.18). On average, equities analysts expect that Benitec Biopharma will post -1.48 EPS for the current year.

Institutional Investors Weigh In On Benitec Biopharma

Several large investors have recently bought and sold shares of BNTC. Infinitum Asset Management LLC raised its stake in Benitec Biopharma by 435.7% in the 1st quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company’s stock valued at $14,636,000 after purchasing an additional 915,000 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Benitec Biopharma by 77.6% in the second quarter. Geode Capital Management LLC now owns 415,211 shares of the biotechnology company’s stock valued at $4,859,000 after buying an additional 181,391 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Benitec Biopharma by 219.4% in the second quarter. Ameriprise Financial Inc. now owns 109,925 shares of the biotechnology company’s stock worth $1,286,000 after buying an additional 75,507 shares in the last quarter. GAMMA Investing LLC boosted its position in Benitec Biopharma by 1,104.3% during the first quarter. GAMMA Investing LLC now owns 77,605 shares of the biotechnology company’s stock worth $1,010,000 after acquiring an additional 71,161 shares during the last quarter. Finally, Goldman Sachs Group Inc. purchased a new stake in Benitec Biopharma during the 1st quarter valued at about $597,000. 52.19% of the stock is currently owned by hedge funds and other institutional investors.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.